G-protein-coupled receptor kinase 2 and endothelial dysfunction: Molecular insights and pathophysiological mechanisms

Journal of Smooth Muscle Research

Volumn 51, Issue 1, 2015, Pages 37-49

  Taguchi, Kumiko ^a   Matsumoto, Takayuki ^a   Kobayashi, Tsuneo ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Akt eNOS signaling pathway; Endothelial dysfunction; GRK2; NO production; arrestin 2

Indexed keywords

ADRBK1 PROTEIN, HUMAN; BETA ARRESTIN; ENDOTHELIUM DERIVED RELAXING FACTOR; G PROTEIN COUPLED RECEPTOR KINASE 2; NITRIC OXIDE; RETINA S ANTIGEN;

ANIMAL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMAN; INSULIN RESISTANCE; METABOLISM; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ANIMALS; ARRESTINS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; ENDOTHELIUM-DEPENDENT RELAXING FACTORS; G-PROTEIN-COUPLED RECEPTOR KINASE 2; HUMANS; INSULIN RESISTANCE; NITRIC OXIDE; OBESITY; SIGNAL TRANSDUCTION;

EID: 84958985690     PISSN: 09168737     EISSN: 18848796     Source Type: Journal    
DOI: 10.1540/jsmr.51.37     Document Type: Article

References (86)

1. Frankel DS, Meigs JB, Massaro JM, Wilson PW, O'Donnell CJ, D'Agostino RB, Tofler GH. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the framingham offspring study. Circulation. 2008; 118(24): 2533-9.
2. Pieper GM. Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction. Hypertension. 1998; 31(5): 1047-60.
3. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhoric rat liver: endothelial dysfunction in portal hypertension. Gastroenterology. 1998; 114(2): 344-51.
4. Eckel RH, Wassef M, Chait A, Sobel B, Barrett E, King G, Lopes-Virella M, Reusch J, Ruderman N, Steiner G, Vlassara H. Prevention conference VI: diabetes and cardiovascular disease: writing group ii: pathogenesis of atherosclerosis in diabetes. Circulation. 2002; 105(18): e138-43.
5. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol. 2004; 286(5): H1597-602.
6. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension. 1999; 33(5): 1130-4.
7. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001; 37(4): 1053-9.
8. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, Norgiolini S, Bracco C, Porcellati C. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004; 43(5): 963-9.
9. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002; 3(9): 639-50.
10. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science. 2005; 308(5721): 512-7.
11. Whalen EJ, Foster MW, Matsumoto A, Ozawa K, Violin JD, Que LG, Nelson CD, Benhar M, Keys JR, Rockman HA, Koch WJ, Daaka Y, Lefkowitz RJ, Stamler JS. Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell. 2007; 129(3): 511-22.
12. Taguchi K, Kobayashi T, Takenouchi Y, Matsumoto T, Kamata K. Angiotensin II causes endothelial dysfunction via the GRK2/Akt/eNOS pathway in aortas from a murine type 2 diabetic model. Pharmacol Res. 2011; 64(5): 535-46.
13. Taguchi K, Kobayashi T, Matsumoto T, Kamata K. Dysfunction of endothelium-dependent relaxation to insulin via PKC-mediated GRK2/Akt activation in aortas of ob/ob mice. Am J Physiol Heart Circ Physiol. 2011; 301(2): H571-83.
14. Taguchi K, Matsumoto T, Kamata K, Kobayashi T. Inhibitor of G protein-coupled receptor kinase 2 normalizes vascular endothelial function in type 2 diabetic mice by improving β-arrestin 2 translocation and ameliorating Akt/eNOS signal dysfunction. Endocrinology. 2012; 153(7): 2985-96.
15. Taguchi K, Matsumoto T, Kamata K, Kobayashi T. G protein-coupled receptor kinase 2, with β-arrestin 2, impairs insulin-induced Akt/endothelial nitric oxide synthase signaling in ob/ob mouse aorta. Diabetes. 2012; 61(8): 1978-85.
16. Taguchi K, Matsumoto T, Kamata K, Kobayashi T. Suppressed G-protein-coupled receptor kinase 2 activity protects female diabetic-mouse aorta against endothelial dysfunction. Acta Physiol (Oxf). 2013; 207(1): 142-55.
17. Pao CS, Barker BL, Benovic JL. Role of the amino terminus of G protein-coupled receptor kinase 2 in receptor phosphorylation. Biochemistry. 2009; 48(30): 7325-33.
18. Cohn HI, Xi Y, Pesant S, Harris DM, Hyslop T, Falkner B, Eckhart AD. G protein-coupled receptor kinase 2 expression and activity are associated with blood pressure in black Americans. Hypertension. 2009; 54(1): 71-6.
19. Premont RT, Gainetdinov RR. Physiological roles of G protein-coupled receptor kinases and arrestins. Annu Rev Physiol. 2007; 69: 511-34.
20. Harris DM, Cohn HI, Pesant S, Eckhart AD. GPCR signalling in hypertension: role of GRKs. Clin Sci (Lond). 2008; 115(3): 79-89.
21. Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. Annu Rev Biochem. 1998; 67: 653-92.
22. Huang CC, Yoshino-Koh K, Tesmer JJ. A surface of the kinase domain critical for the allosteric activation of G protein-coupled receptor kinases. J Biol Chem. 2009; 284(25): 17206-15.
23. Sallese M, Mariggiò S, D'Urbano E, Iacovelli L, De Blasi A. Selective regulation of Gq signaling by G protein-coupled receptor kinase 2: direct interaction of kinase N terminus with activated Gaq. Mol Pharmacol. 2000; 57(4): 826-31.
24. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature. 2002; 415(6868): 206-12.
25. Hata JA, Koch WJ. Phosphorylation of G protein-coupled receptors: GPCR kinases in heart disease. Mol Intervent. 2003; 3(5): 264-72.
26. Reiter E, Lefkowitz RJ. GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab. 2006; 17(4): 159-265.
27. Lymperopoulos A. GRK2 and β-arrestins in cardiovascular disease: Something old, something new. Am J Cardiovasc Dis. 2011; 1(2): 126-37.
28. Krupnick JG, Benovic JL. The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol. 1998; 38: 289-319.
29. Choi DJ, Koch WJ, Hunter JJ, Rockman HA. Mechanism of beta-adrenergic receptor desensitization in cardiac hypertrophy is increased beta-adrenergic receptor kinase. J Biol Chem. 1997; 272(27): 17223-9.
30. Ungerer M, Kessebohm K, Kronsbein K, Lohse MJ, Richardt G. Activation of beta-adrenergic receptor kinase during myocardial ischemia. Circ Res. 1996; 79(3): 455-60.
31. Ungerer M, Böhm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation. 1993; 87(2): 454-63.
32. Vinge LE, Øie E, Andersson Y, Grøgaard HK, Andersen G, Attramadal H. Myocardial distribution and regulation of GRK and beta-arrestin isoforms in congestive heart failure in rats. Am J Physiol Heart Circ Physiol. 2001; 281(6): H2490-9.
33. Anderson KM, Eckhart AD, Willette RN, Koch WJ. The myocardial beta-adrenergic system in spontaneously hypertensive heart failure (SHHF) rats. Hypertension. 1999; 33(1 Pt 2): 402-7.
34. Theilade J, Strøm C, Christiansen T, Haunsø S, Sheikh SP. Differential G protein receptor kinase 2 expression in compensated hypertrophy and heart failure after myocardial infarction in the rat. Basic Res Cardiol. 2003; 98(2): 97-103.
35. Gros R, Benovic JL, Tan CM, Feldman RD. G-protein-coupled receptor kinase activity is increased in hypertension. J Clin Invest. 1997; 99(9): 2087-93.
36. Garcia-Guerra L, Nieto-Vazquez I, Vila-Bedmar R, Jurado-Pueyo M, Zalba G, Díez J, Murga C, Fernández-Veledo S, Mayor F Jr, Lorenzo M. G protein-coupled receptor kinase 2 plays a relevant role in insulin resistance and obesity. Diabetes. 2010; 59(10): 2407-17.
37. Penela P, Ribas C, Mayor F Jr. Mechanisms of regulation of the expression and function of G proteincoupled receptor kinases. Cell Signal. 2003; 15(11): 973-81.
38. Ciccarelli M, Cipolletta E, Iaccarino G. GRK2 at the control shaft of cellular metabolism. Curr Pharm Des. 2012; 18(2): 121-7.
39. Iaccarino G, Barbato E, Cipolletta E, De Amicis V, Margulies KB, Leosco D, Trimarco B, Koch WJ. Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur Heart J. 2005; 26(17): 1752-8.
40. Penela P, Murga C, Ribas C, Lafarga V, Mayor F Jr. The complex G protein-coupled receptor kinase 2 (GRK2) interactome unveils new physiopathological targets. Br J Pharmacol. 2010; 160(4): 821-32.
41. Bouvier M, Hausdorff WP, De Blasi A, O'Dowd BF, Kobilka BK, Caron MG, Lefkowitz RJ. Removal of phosphorylation sites from the beta 2-adrenergic receptor delays onset of agonist-promoted desensitization. Nature. 1988; 333(6171): 370-3.
42. Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ. beta-Arrestin: a protein that regulates betaadrenergic receptor function. Science. 1990; 248(4962): 1547-50.
43. Watari K, Nakaya M, Kurose H. Multiple functions of G protein-coupled receptor kinases. J Mol Signal. 2014; 9(1): 1.
44. Kelly E, Bailey CP, Henderson G. Agonist-selective mechanisms of GPCR desensitization. Br J Pharmacol. 2008; 153(Suppl 1): S379-88.
45. Ferguson SS, Ménard L, Barak LS, Koch WJ, Colapietro AM, Caron MG. Role of phosphorylation in agonist-promoted beta 2-adrenergic receptor sequestration. Rescue of a sequestration-defective mutant receptor by beta ARK1. J Biol Chem. 1995; 270(42): 24782-9.
46. Ferguson SS, Downey WE 3rd, Colapietro AM, Barak LS, Ménard L, Caron MG. Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science. 1996; 271(5247): 363-6.
47. Thal DM, Yeow RY, Schoenau C, Huber J, Tesmer JJ. Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors. Mol Pharmacol. 2011; 80(2): 294-303.
48. Tachibana H, Naga Prasad SV, Lefkowitz RJ, Koch WJ, Rockman HA. Level of beta-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure. Circulation. 2005; 111(5): 591-7.
49. Lymperopoulos A, Rengo G, Funakoshi H, Eckhart AD, Koch WJ. Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med. 2007; 13(3): 315-23.
50. Lefkowitz RJ, Whalen EJ. β-arrestins: traffic cops of cell signaling. Curr Opin Cell Biol. 2004; 16(2): 162-8.
51. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. Beta-arrestins and cell signaling. Annu Rev Physiol. 2007; 69: 483-510.
52. Schmid CL, Bohn LM. Physiological and pharmacological implications of beta-arrestin regulation. Pharmacol Ther. 2009; 121(3): 285-93.
53. Luttrell LM, Gesty-Palmer D. Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol Rev. 2010; 62(2): 305-30.
54. Cipolletta E, Campanile A, Santulli G, Sanzari E, Leosco D, Campiglia P, Trimarco B, Iaccarino G. The G protein coupled receptor kinase 2 plays an essential role in beta-adrenergic receptor-induced insulin resistance. Cardiovasc Res. 2009; 84(3): 407-15.
55. Usui I, Imamura T, Satoh H, Huang J, Babendure JL, Hupfeld CJ, Olefsky JM. GRK2 is an endogenous protein inhibitor of the insulin signaling pathway for glucose transport stimulation. EMBO J. 2004; 23(14): 2821-9.
56. Sorriento D, Ciccarelli M, Santulli G, Illario M, Trimarco B, Iaccarino G. Trafficking GRK2: Cellular and Metabolic consequences of GRK2 subcellular localization. Transl Med UniSa. 2014; 10: 3-7.
57. Usui I, Imamura T, Babendure JL, Satoh H, Lu JC, Hupfeld CJ, Olefsky JM. G protein-coupled receptor kinase 2 mediates endothelin-1-induced insulin resistance via the inhibition of both Galphaq/11 and insulin receptor substrate-1 pathways in 3T3-L1 adipocytes. Mol Endocrinol. 2005; 19(11): 2760-8.
58. Luan B, Zhao J, Wu H, Duan B, Shu G, Wang X, Li D, Jia W, Kang J, Pei G. Defciency of a beta-arrestin-2 signal complex contributes to insulin resistance. Nature. 2009; 457(7233): 1146-9.
59. Ciccarelli M, Chuprun JK, Rengo G, Gao E, Wei Z, Peroutka RJ, Gold JI, Gumpert A, Chen M, Otis NJ, Dorn GW 2nd, Trimarco B, Iaccarino G, Koch WJ. G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. Circulation. 2011; 123(18): 1953-62.
60. Anis Y, Leshem O, Reuveni H, Wexler I, Ben Sasson R, Yahalom B, Laster M, Raz I, Ben Sasson S, Shafrir E, Ziv E. Antidiabetic effect of novel modulating peptides of G-protein-coupled kinase in experimental models of diabetes. Diabetologia. 2004; 47(7): 1232-44.
61. Takenouchi Y, Kobayashi T, Taguchi K, Matsumoto T, Kamata, K. Gender differences in endothelial function in aortas from type 2 diabetic model mice. J Pharmacol Sci. 2009; 111(1): 91-9.
62. Vanhoutte PM, Shimokawa H, Tang EH, Feletou M. Endothelial dysfunction and vascular disease. Acta Physiol (Oxf). 2009; 196(2): 193-222.
63. Shah V, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K, Sessa WC, Groszmann RJ. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology. 1999; 117(5): 1222-8.
64. Mount PF, Kemp BE, Power DA. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol. 2007; 42(2): 271-9.
65. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399(6736): 601-5.
66. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999; 399(6736): 597-601.
67. Kobayashi T, Taguchi K, Yasuhiro T, Matsumoto T, Kamata K. Impairment of PI3-K/Akt pathway underlies attenuated endothelial function in aorta of type 2 diabetic mouse model. Hypertension. 2004; 44(6): 956-62.
68. Kobayashi T, Taguchi K, Nemoto S, Nogami T, Matsumoto T, Kamata K. Activation of the PDK-1/Akt/ eNOS pathway involved in aortic endothelial function differs between hyperinsulinemic and insulindeficient diabetic rats. Am J Physiol Heart Circ Physiol. 2009; 297(5): H1767-75.
69. Kobayashi T, Taguchi K, Takenouchi Y, Matsumoto T, Kamata K. Insulin-induced impairment via peroxynitrite production of endothelium-dependent relaxation and sarco/endoplasmic reticulum Ca2+-ATPase function in aortas from diabetic rats. Free Radic Biol Med 2007; 43(3): 431-43.
70. Lee JH, Palaia T, Ragolia L. Impaired insulin-mediated vasorelaxation in diabetic Goto-Kakizaki rats is caused by impaired Akt phosphorylation. Am J Physiol Cell Physiol. 2009; 296(2): C327-38.
71. Lymperopoulos A, Rengo G, Funakoshi H, Eckhart AD, Koch WJ. Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med. 2007; 13(3): 315-23.
72. Pei G, Tiberi M, Caron MG, Lefkowitz RJ. An approach to the study of G-protein-coupled receptor kinases: an in vitro-purified membrane assay reveals differential receptor specificity and regulation by G β? subunits. Proc Natl Acad Sci U S A. 1994; 91(9): 3633-6.
73. Ahn S, Kim J, Hara MR, Ren XR, Lefkowitz RJ. β-Arrestin-2 Mediates Anti-apoptotic Signaling through Regulation of BAD Phosphorylation. J Biol Chem. 2009; 284(13): 8855-65.
74. Hall RA, Premont RT, Lefkowitz RJ. Heptahelical receptor signaling: beyond the G protein paradigm. J Cell Biol. 1999; 145(5): 927-32.
75. Coureuil M, Lécuyer H, Scott MG, Boularan C, Enslen H, Soyer M, Mikaty G, Bourdoulous S, Nassif X, Marullo S. Meningococcus Hijacks a β2-adrenoceptor/β-Arrestin pathway to cross brain microvasculature endothelium. Cell. 2010; 143(7): 1149-60.
76. Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL, Lefkowitz RJ. Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci U S A. 2001; 98(5): 2449-54.
77. DeFea KA, Zalevsky J, Thoma MS, Déry O, Mullins RD, Bunnett NW. beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol. 2000; 148(6): 1267-81.
78. Barnes WG, Reiter E, Violin JD, Ren XR, Milligan G, Lefkowitz RJ. β-Arrestin 1 and Galphaq/11 coordinately activate RhoA and stress fiber formation following receptor stimulation. J Biol Chem. 2005; 280(9): 8041-50.
79. Bhattacharya M, Anborgh PH, Babwah AV, Dale LB, Dobransky T, Benovic JL, Feldman RD, Verdi JM, Rylett RJ, Ferguson SS. Beta-arrestins regulate a Ral-GDS Ral effector pathway that mediates cytoskeletal reorganization. Nat Cell Biol. 2002; 4(8): 547-55.
80. Skafar DF, Xu R, Morales J, Ram J Sowers JR. Clinical review 91: female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab. 1997; 82(12): 3913-8.
81. Sowers JR. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med. 1998; 158(6): 617-21.
82. Kaseta JR, Skafar DF, Ram JL, Jacober SJ, Sowers JR. Cardiovascular disease in the diabetic women. J Clin Endocrinol Metab. 1999; 84(6): 1835-8.
83. Taguchi K, Matsumoto T, Kamata K, Kobayashi T. Akt/eNOS pathway activation in endothelium-dependent relaxation is preserved in aortas from female, but not from male, type 2 diabetic mice. Pharmacol Res. 2012; 65(1): 56-65.
84. Ciccarelli M, Sorriento D, Franco A, Fusco A, Del Giudice C, Annunziata R, Cipolletta E, Monti MG, Dorn GW 2nd, Trimarco B, Iaccarino G. Endothelial G protein-coupled receptor kinase 2 regulates vascular homeostasis through the control of free radical oxygen species. Arterioscler Thromb Vasc Biol. 2013; 33(10): 2415-24.
85. Rivas V, Carmona R, Muñoz-Chápuli R, Mendiola M, Nogués L, Reglero C, Miguel-Martín M, García-Escudero R, Dorn GW 2nd, Hardisson D, Mayor F Jr, Penela P. Developmental and tumoral vascularization is regulated by G protein-coupled receptor kinase 2. J Clin Invest. 2013; 123(11): 4714-30.
86. Stevenson NL, Martin-Martin B, Freeman J, Kriston-Vizi J, Ketteler R, Cutler DF. G protein-coupled receptor kinase 2 moderates recruitment of THP-1 cells to the endothelium by limiting histamine-invoked Weibel-Palade body exocytosis. J Thromb Haemost. 2014; 12(2): 261-72.